MX360390B - Inhibidores de la proteina 90 de choque termico (hsp90). - Google Patents
Inhibidores de la proteina 90 de choque termico (hsp90).Info
- Publication number
- MX360390B MX360390B MX2013011532A MX2013011532A MX360390B MX 360390 B MX360390 B MX 360390B MX 2013011532 A MX2013011532 A MX 2013011532A MX 2013011532 A MX2013011532 A MX 2013011532A MX 360390 B MX360390 B MX 360390B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- formulae
- compound
- formula
- effective amount
- Prior art date
Links
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472061P | 2011-04-05 | 2011-04-05 | |
| PCT/US2012/032371 WO2012138894A1 (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013011532A MX2013011532A (es) | 2014-08-22 |
| MX360390B true MX360390B (es) | 2018-10-31 |
Family
ID=48166734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011532A MX360390B (es) | 2011-04-05 | 2012-04-05 | Inhibidores de la proteina 90 de choque termico (hsp90). |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9346808B2 (enExample) |
| EP (1) | EP2694505B1 (enExample) |
| JP (1) | JP6266506B2 (enExample) |
| KR (1) | KR102010222B1 (enExample) |
| CN (1) | CN103582642B (enExample) |
| AU (1) | AU2012240077C1 (enExample) |
| BR (1) | BR112013025634A2 (enExample) |
| CA (1) | CA2832530C (enExample) |
| EA (1) | EA201391334A1 (enExample) |
| MX (1) | MX360390B (enExample) |
| WO (1) | WO2012138894A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| AU2010303343B2 (en) | 2009-10-07 | 2015-11-19 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as HSP90 inhibitors |
| EP2694505B1 (en) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| EA024647B1 (ru) | 2011-04-05 | 2016-10-31 | Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч | ИНГИБИТОРЫ Hsp90 |
| CN109374889B (zh) | 2011-07-08 | 2022-04-19 | 索隆-基特林癌症研究协会 | 标记的hsp90抑制剂的用途 |
| US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| WO2015023976A2 (en) | 2013-08-16 | 2015-02-19 | Memorial Sloan-Kettering Cancer Center | Selective grp94 inhibitors and uses thereof |
| US9994573B2 (en) * | 2013-12-23 | 2018-06-12 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| JP6835709B2 (ja) | 2014-09-17 | 2021-02-24 | メモリアル スローン ケタリング キャンサー センター | Ｈｓｐ９０を標的とした炎症及び感染のイメージング及び療法 |
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| EA201890623A1 (ru) | 2015-10-05 | 2018-09-28 | Мемориал Слоун Кеттеринг Кэнсер Сентр | Рациональная комбинированная терапия для лечения рака |
| CN111683658A (zh) * | 2017-06-23 | 2020-09-18 | 萨缪斯治疗股份有限公司 | 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4903922B2 (ja) | 1997-05-14 | 2012-03-28 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 選択された蛋白質を分解する複合化合物 |
| WO2000061578A1 (en) | 1999-04-09 | 2000-10-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| JP2005519848A (ja) | 2000-11-02 | 2005-07-07 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｈｓｐ９０に結合するための小分子組成物 |
| BR0210391A (pt) | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| EP2336133A1 (en) | 2001-10-30 | 2011-06-22 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| EP1450784A4 (en) | 2001-11-09 | 2005-02-09 | Conforma Therapeutics Corp | HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE |
| US7473699B2 (en) | 2002-02-28 | 2009-01-06 | Astrazeneca Ab | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents |
| EP1620564A4 (en) | 2003-04-18 | 2008-03-12 | Cytovia Inc | METHODS FOR TREATING DISEASES INDUCING APOPTOSIS INDUCTION AND SCREENING ASSAYS |
| EP2145888A1 (en) | 2003-09-18 | 2010-01-20 | Conforma Therapeutics Corporation | Deazapurine derivatives as HSP90-Inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| EP1962863A4 (en) | 2005-12-22 | 2010-11-24 | Conforma Therapeutics Corp | ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90 |
| WO2007134298A2 (en) * | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| CA2662937A1 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| FR2906824B1 (fr) | 2006-10-09 | 2008-12-26 | Roger Mondelin Sas Soc Par Act | Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) * | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| NZ579635A (en) * | 2007-03-20 | 2011-07-29 | Curis Inc | Fused amino pyridine as hsp90 inhibitors |
| US20080234297A1 (en) * | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| US20100240656A1 (en) * | 2007-07-12 | 2010-09-23 | Oryzon Genomics, S.A. | Compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| CA2705579A1 (en) * | 2007-11-14 | 2009-05-22 | Myriad Pharmaceuticals, Inc. | Therapeutic compounds and their use in treating diseases and disorders |
| MX2011007612A (es) | 2009-01-16 | 2012-01-20 | Curis Inc | Aminopiridinas fusionadas para el tratamiento de tumores del cerebro. |
| GB0905328D0 (en) * | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
| ES2767176T3 (es) * | 2009-07-17 | 2020-06-16 | CleanSpace IP Pty Ltd | Respirador |
| GB0914543D0 (en) * | 2009-08-20 | 2009-09-30 | Ge Healthcare Ltd | Radioiodination method |
| AU2010303343B2 (en) | 2009-10-07 | 2015-11-19 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as HSP90 inhibitors |
| EA024647B1 (ru) | 2011-04-05 | 2016-10-31 | Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч | ИНГИБИТОРЫ Hsp90 |
| EP2694505B1 (en) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| WO2015023976A2 (en) | 2013-08-16 | 2015-02-19 | Memorial Sloan-Kettering Cancer Center | Selective grp94 inhibitors and uses thereof |
-
2012
- 2012-04-05 EP EP12717520.6A patent/EP2694505B1/en active Active
- 2012-04-05 AU AU2012240077A patent/AU2012240077C1/en not_active Ceased
- 2012-04-05 US US14/009,976 patent/US9346808B2/en active Active
- 2012-04-05 EA EA201391334A patent/EA201391334A1/ru unknown
- 2012-04-05 CA CA2832530A patent/CA2832530C/en active Active
- 2012-04-05 JP JP2014503994A patent/JP6266506B2/ja not_active Expired - Fee Related
- 2012-04-05 CN CN201280027256.0A patent/CN103582642B/zh not_active Expired - Fee Related
- 2012-04-05 KR KR1020137029259A patent/KR102010222B1/ko not_active Expired - Fee Related
- 2012-04-05 WO PCT/US2012/032371 patent/WO2012138894A1/en not_active Ceased
- 2012-04-05 BR BR112013025634A patent/BR112013025634A2/pt not_active IP Right Cessation
- 2012-04-05 MX MX2013011532A patent/MX360390B/es active IP Right Grant
-
2016
- 2016-05-20 US US15/160,293 patent/US9926321B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012240077A1 (en) | 2013-10-31 |
| NZ616758A (en) | 2016-01-29 |
| EP2694505B1 (en) | 2022-04-27 |
| WO2012138894A1 (en) | 2012-10-11 |
| CA2832530A1 (en) | 2012-10-11 |
| EP2694505A1 (en) | 2014-02-12 |
| KR20140062429A (ko) | 2014-05-23 |
| US20140088121A1 (en) | 2014-03-27 |
| US9346808B2 (en) | 2016-05-24 |
| WO2012138894A4 (en) | 2012-12-06 |
| CN103582642A (zh) | 2014-02-12 |
| US9926321B2 (en) | 2018-03-27 |
| US20160264577A1 (en) | 2016-09-15 |
| AU2012240077B2 (en) | 2017-04-20 |
| AU2012240077C1 (en) | 2017-08-10 |
| BR112013025634A2 (pt) | 2016-07-19 |
| CA2832530C (en) | 2021-02-16 |
| MX2013011532A (es) | 2014-08-22 |
| JP2014510148A (ja) | 2014-04-24 |
| JP6266506B2 (ja) | 2018-01-24 |
| KR102010222B1 (ko) | 2019-08-13 |
| CN103582642B (zh) | 2021-05-11 |
| EA201391334A1 (ru) | 2014-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360390B (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
| NZ603155A (en) | Phospholipid drug analogs | |
| EA201391337A1 (ru) | Ингибиторы hsp90 | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| WO2010132999A8 (en) | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics | |
| PH12015500513A1 (en) | Methods for the treatment of locally advanced breast cancer | |
| EA201300860A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| MX2014008021A (es) | Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. | |
| BR112013022801A2 (pt) | combinações de terapia para malignidades hematológicas | |
| WO2012078757A3 (en) | Combination for breast cancer therapy with hsp90 inhibitory compounds | |
| NZ726366A (en) | Syk inhibitors | |
| WO2009127669A3 (en) | Ido inhibitors and therapeutic uses thereof | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| WO2012141796A3 (en) | Prostate cancer therapy with hsp90 inhibitory compounds | |
| MX2011008910A (es) | Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson. | |
| MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
| MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| EA201270347A1 (ru) | Производные апогоссиполона в качестве противоопухолевых агентов | |
| TW201129361A (en) | Methods for treating pain | |
| IN2014KN01113A (enExample) | ||
| NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole | |
| IN2014CN02315A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |